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Abstract 
Background: Cerebral vasospasm that 
occurs after subarachnoid hemorrhage 
(SAH) can be an important cause of 
mortality and morbidity for patients 
successfully operated for a cerebral 
aneurysm. 
Methods: Five cases of prompt diagnostic 
and surgical treatment of a cerebral 
aneurysm, with important SAH on cerebral 
computed tomography (CT) at onset, are 
presented. All patients were admitted in a 
poor neurological state and developed 
severe vasospasm. Both, the correct clipping 
of the aneurysm and the cerebral vasospasm 
were angiographic demonstrated in all 
cases. Two patients showed complete 
obliteration of one carotid artery. 
Results: Postoperatory, four of the 
patients were treated with intrathecally 
administered nimodipine (10mg/50ml). In 
three cases, the procedure caused the 
reverse of the vasospasm and clinical 
improvement of the patients. Their clinical 
outcomes were very good and were 
discharged with minimal neurological 
deficits. In one case, repeated intraarterial 
administration of nimodipine, showed no 
reduction of the vasospasm, and no 
improvement of patient’s clinical status. 
The patient was conscious, but presented 
focal neurological deficits (hemiplegia and 
aphasia). One patient did not benefit from 
this treatment and had a poor clinical 
outcome, remaining in a vegetative state. 
Conclusions: Cerebral vasoconstriction 
after SAH could be an important obstacle in 
obtaining very good results in aneurysm 
surgery. Intra-arterial administration of 
nimodipine is an important and useful 
treatment, but good results in reversal 
severe cerebral vasospasm are not always 
mandatory. 
Key words: cerebral aneurysms, 
cerebral vasospasm, clipping of the 
aneurysm, postoperative results. 
Introduction 
Cerebral vasospasm is a known source of 
considerable morbidity and even mortality 
following subarachnoid hemorrhage (SAH) 
(17, 20). It is a prolonged, sometimes 
severe, but ultimately reversible cerebral 
arterial narrowing that occurs days after 
subarachnoid space bleeding. 
Angiographic vasospasm was first 
described by a neurosurgeon, Ecker, along 
with a radiologist, Riemenschneider, in 
Syracuse, New York, in 1951 (5). A number 
of studies described the direct relationship 
between the location and amount of 
subarachnoid blood seen on admission 
computed tomography (CT) and the risk 
and distribution of angiographic vasospasm 
(3, 21). In 1980, Fisher and co-workers 
provided a useful predictive grading scale 
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for vasospasm based on the location and 
thickness of the clot (10). 
First neurosurgical studies (12), which 
evaluated the impact of clinical and 
angiographic vasospasm over patients’ 
outcome, estimated that roughly one half of 
patients with SAH developed angiographic 
vasospasm, one half of this group would 
become symptomatic and one half of these 
symptomatic patients would die of cerebral 
infarction. Modern perioperative care of 
SAH clearly improved this situation and the 
aggressive treatment of symptomatic 
vasospasm have reduced the combined risk 
of all morbidity and mortality due to 
vasospasm to between 10% and 15%, in 
more recent SAH patient series (2, 8). 
The aim of this study is to present five 
cases with severe angiographic and clinical 
vasospasm, in which, despite an early 
surgery that had provided a correct clipping 
of the aneurysms, and allowed an aggressive 
perioperative medical treatment of 
vasospasm, we faced important morbidity 
due to clinical vasospasm. 
Material and methods 
We reported the cases of five patients 
with important subarachnoid hemorrhage 
on CT scan at admission and who were 
diagnosed by four vessels digital subtraction 
angiography with cerebral aneurysms. In all 
cases, cerebral vasospasm implied the 
simultaneous presence of angiographic 
vasospasm and clinical vasospasm. In all 
cases, angiographic vasospasm was noted 
before surgery, at that time when the 
diagnostic cerebral arteriography was 
performed. 
Admission Glasgow Coma Scale was 
between 6 and 10 points. As a rule for 
treatment of anterior circulation aneurysms 
in our neurosurgical department, we 
performed surgical clipping of the 
aneurysms as soon as possible after its 
diagnosis. In all five patients, we performed 
early aneurysm clipping, which afforded us 
the opportunity to mechanically reduce the 
subarachnoid clot burden and reduced the 
vasospasm risk. Interval between diagnostic 
and surgery ranged between 24 to 72 hours. 
Both, the correct clipping of the aneurysm 
and the postoperative presence of arterial 
vasospasm were angiographic demonstrated 
in all cases. 
Nimodipine administration started at 
admission in continuous intravenous 
perfusion (at a speed varying between 8-12 
ml/h depending on blood pressure). In four 
cases, local intra-arterial nimodipine was 
infused during control arteriography. In 
one case, this procedure was repeated three 
times postoperatively. 
Illustrative case 1 
A 68 years female was admitted to our 
clinic, 8 days after the onset of symptoms, 
with the diagnostic of SAH. At admission 
she was in a poor neurological state, with a 
GCS of 8 points, somnolence, third left 
cranial nerve palsy, right hemiparesis and 
motor aphasia. Initial cerebral CT scan 
showed blood in the main subarachnoid 
cisterns and in most of the cortical sulci 
(Figure 1A). Cerebral angiography, 
performed in the next day after her 
admission, revealed a left posterior 
communicating artery aneurysm and an 
important cerebral vasospasm (Figure 1B). 
She was operated within 24 hours after 
admission, and the clipping of the left 
posterior communicating aneurysm was 
performed. In the second day after surgery, 
we performed control cerebral angiography 
(Figure 2B, C, D). It demonstrated the 
correct clipping of the aneurysm, but 
revealed a severe and diffuse cerebral 
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vasospasm which involved anterior cerebral 
artery (ACA) andmiddle cerebral artery 
(ACM). In the same session, using the 
intra-arterial micro-catheter, we 
administrated locally nimodipine, in the 
both ACA and ACM arteries. Due to the 
severity of the vasospasm, the presence of 
symptomatic infarcts and the lack of the 
possibility to perform angioplasty, we 
repeated local administration of nimodipine 
by the mean of intra-arterial catheters two 
more times, in the 4th and, respectively, the 
6th postoperative day. No signs of the 
resolving of the intensity of the vasospasm 
were demonstrated. Cerebral CT scans 
showed diffuse area of infraction in the 
ACA and ACM supplying territories on 
both sides (Figure 2A). Continuous 
intravenous perfusion of nimodipine was 
maintained 14 days after surgery. Despite a 
good evolution of her neurological status in 
the first postoperative week, meaning the 
improvement of the consciousness, right 
hemiparesis and aphasia, her neurological 
evolution became stationary in the second 
and third postoperative week and showed 
progressive worsening starting with the 
fourth week. After one month from surgery 
her GOS score was 3.  
Her evolution complicated with 
bronchopneumonia and died 48 days after 
surgery. 
Illustrative case 2 
A 45 years old male was admitted to our 
clinic, 3 days after the onset of symptoms, 
presenting severe headache, neck stiffness, 
photophobia, confusion and a slight left 
hemiparesis. Initial cerebral CT scan 
(Figure 3A) showed subarachnoid 
hemorrhage and a thick clot in the anterior 
interhemispheric fissure (grade 3 on 
Fischer scale). Cerebral angiography, 
performed within 48 hours of his 
admission, revealed an anterior 
communicating artery aneurysm and 
vasospasm on the proximal portion of the 
left ACA (segment A1) and its distal 
branches (Figure 3B). He was operated 
after three days of his admission, and the 
clipping of the anterior communicating 
artery aneurysm was performed. In the 
third postoperative day, he showed 
increasing of his left hemiparesis and 
became somnolent. 
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Figure 1. Preoperative images: (A) Native CT scan showing blood in the main subarachnoid cisterns and in 
most of the cortical sulci; Fischer scale–2, (B) four vessels cerebral angiography showed a left posterior 
communicating artery aneurysm and an important and diffuse cerebral vasospasm 
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Figure 2. Postoperative images (48 hours after surgery): (A) – native CT scan showing ischemic hipodensities in 
the left ACA and ACM territories, (B, C, D) control cerebral angiography showed the correct clipping of the 
aneurysm and a severe and persistent vasospasm, which did not resolve after intra-arterial infusion of nimodipine 
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Figure 3. Preoperative images: (A) Native CT scan showing subarachnoid hemorrhage and a thick clot in the 
anterior interhemispheric fissure (grade 3 on Fischer scale), (B) four vessels cerebral angiography showed an 
anterior communicating artery aneurysm and vasospasm on the proximal portion of the left ACA (segment A1) 
and its distal branches 
 
 
 
Romanian Neurosurgery (2013) XX 1: 57 - 65          61 
 
 
 
Control angiography was performed 
four days after surgery, and demonstrated 
the correct clipping of the aneurysm 
(Figure 4B, C, D). Because of the increased 
vessels narrowing in the proximal and distal 
branches of the left ACA, compared with 
the diagnostic angiography, we locally 
injected nimodipine, using the intra-arterial 
micro-catheter, in order to reduce 
vasospasm in those arteries. Control CT 
scans showed the resolution of the initial 
frontal interhemispheric clot, and no other 
sign of focal ischemia (Figure 4A). 
Continuous intravenous perfusion of 
nimodipine was maintained 8 days after 
surgery, and it was continued orally. The 
medical treatment went successfully and 
the patient had no ischemic sequelae. He 
had a very good recovery and presented no 
permanent neurological deficits at 3 months 
follow-up (GOS - 15 points). 
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Figure 4. Postoperative images (4 days after 
surgery): (A) – native CT scan showing resolution of 
the initial frontal interhemispheric clot, and no other 
sign of focal ischemia, (B, C, D) control cerebral 
angiography showed the correct clipping of the 
aneurysm and  moderate vasospasm in the proximal 
and distal branches of the left ACA 
Results 
Patient outcome was directly dependent 
on admission GCS, time interval between 
onset of symptoms and diagnostic/surgical 
treatment and intensity of vasospasm. It 
mainly affected the arterial branches of the 
anterior part of the circle of Willis. 
Unfortunately, two important means of 
reversing vasospasm were not used in our 
clinic: intra-arterial papaverine 
administration (lack of experience) and 
 
 
 
62          Stefanescu et al          Cerebral Vasospasm 
 
 
 
percutaneous transluminal balloon 
angioplasty (lack of materials). Only in one 
patient we noted the decreasing of 
vasospasm intensity at the control 
angiography. In two cases we encountered 
severe vasospasm, and, in the other three, 
the intensity was moderate. In one patient 
the aneurysm re-bleed before surgery, 
which delayed the clipping of aneurysm 
and led to development of hydrocephalus. 
The patients who presented a severe 
angiographic and clinical vasospasm, with 
signs of infarction on CT scan, had a poor 
outcome. One died of non-neurological 
complications (bronchopneumonia), and 
the other had permanent sequlae (GOS - 
3). In the other three patients, the medical 
treatment successfully reversed ischemia 
and vasospasm, and the outcome at 3 
months after surgery was good, with 
minimal neurological deficits. 
Discussion 
A review of the literature found that the 
overall incidence of angiographic vasospasm 
after SAH was roughly 50%, although the 
estimates ranged from 20% to nearly 100% 
(10). The variation appeared due to 
inconsistencies in the timing of cerebral 
angiography and definitions of vasospasm 
used (7). In a recent randomized trial, 
Findlay and co-workers, assessing the 
amount of subarachnoid clot on the 
admission CT scan, showed that almost 
60% of patients with thick clots developed 
moderate to severe angiographic vasospasm 
in at least one major cerebral artery (9). 
 
TABLE 1 
Important clinical and imagistic parameters of a series of five patients with angiographic 
and symptomatic vasospasm 
 Case 1 Case 2 Case 3 Case 4 Case 5 
Sex  M F F M M 
Age  45 68 58 41 51 
Admission GCS 10 8 8 6 10 
Fischer scale 3 2 4 4 2 
HuntαHess 2 3 3 4 2 
Interval between 
onset/admission 
3 days 8 days 5 days 4 days 5 days 
Interval between 
diagnostic/surgery 
48h 24h 72h (aneurysm 
re-rupture) 
24h 24h 
Vasospasm before 
surgery 
yes yes yes yes yes 
Vasospasm after 
surgery 
increased increased increased decreased increased 
Other SAH related 
complications 
none hydrocephalus Re-
rupture/hydroce
phalus 
none none 
1 months follow-up 
(outcome) 
Good 
(GOS- 5) 
Poor (GOS-3) Poor (GOS-3) Good 
(GOS-4) 
Good 
(GOS-5) 
4 months follow-up 
(outcome) 
Good 
(GOS -5) 
Death No dates Good 
(GOS-5) 
Good 
(GOS – 5) 
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Related to this subject is the 
demonstration that reducing the 
subarachnoid clot amount by early surgery 
(within 48 hours of rupture) decreases the 
risk of severe angiographic vasospasm (9, 
19). Delayed-onset cerebral ischemia and 
infarction account for 15 to 20% of all 
unfavorable outcomes (22). 
Risk factors for symptomatic vasospasm 
are: thick subarachnoid clots on cerebral 
CT, poor neurological condition on 
admission, age younger than 35 and older 
than 65, cigarette smoking, preexisting 
hypertension, incomplete circle of Willis 
(19). 
The most important measure in 
preventing vasospastic ischemia was 
avoiding of post-SAH hypovolemia, 
hypotension and raised intracranial 
pressure. Because all our patients presented 
angiographic and clinical vasospasm, we 
increased fluid administration in order to 
maintained systemic blood pressure in a 
moderate hypertensive range (140 to 160 
mmHg). Deliberate hypervolemia has not 
been proven to reduce symptomatic 
ischemia and can precipitate 
cardiopulmonary decompensation in older 
patients (1). We did not use transcranial 
Doppler in monitoring blood velocities, as a 
test to demonstrate the presence of 
angiographic vasospasm. 
Nimodipine prevents intracellular 
calcium increases by blocking 
dihydropyridine-sensitive (L-type) calcium 
channels and in a series of randomized 
controlled trials has had a modest but 
statistically significant beneficial impact on 
clinical outcome after aneurysmal SAH (13, 
15). The largest and most compelling study 
was the British Aneurysm Nimodipine 
Trial (BRANT) (16), which encompassed 
554 patients of all grades, who received 
treatment within 4 days of hemorrhage, 
consisting of either placebo or nimodipine 
60 mg every 4 hours for 21 days. Results 
were as follow: cerebral infarction occurred 
in 22% of nimodipine-treated patients 
versus 33% of those who received placebo, 
and poor outcomes (severe disability, 
vegetative state and death) were 
significantly reduced in the nimodipine 
group, 20% versus 33% for placebo (16). 
In our series, nimodipine administration 
started at admission in continuous 
intravenous perfusion, at a speed varying 
from 8-12ml/h depending on blood 
pressure, and lasted for more than one 
week after surgery (range between 8 and 14 
days). In all cases, parenteral administration 
of nimodipine was followed by oral up-
taking for more than 7 days. In four cases, 
local cerebral intra-arterial nimodipine was 
infused during control angiography, and in 
one patient, the procedure was repeated 
three times after surgery, only for the mean 
to overcome the vasospasm. 
Numerous treatments for cerebral 
arterial vasospasm have been evaluated. It is 
worth to be noted that vasospasm in 
humans does not respond to the large 
variety of drugs that reverse experimental 
vasospasm in animal models (11). Some of 
the treatment options in post-SAH 
vasospasm can only:  
(a) prevent, but not reduce vasospasm - 
early surgery with removal of blood clots, 
avoidance of hypovolemia and anemia  
(b) protect the brain from ischemic 
injuries – calcium channel blockers, N-
metil-D-aspartate (NMDA) receptor 
antagonists, free radical scavengers (e.g 
tirilazad mesylate, nicaraven) 
(c) improve the rheologic properties of 
intravascular blood to enhance perfusion of 
ischemic zones (e.g plasma, albumin, low 
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molecular weight dextran) (11) 
 The only vasospasm treatment options 
that have been proved by many studies, to 
reverses ischemia or vasospasm are 
presented in Table 2 (7). 
 
TABLE 2 
Management of vasospasm and cerebral 
ischemia after aneurysmal SAH 
Strategies for vasospasm and/or cerebral 
ischemia reversal after aneurysmal 
subarachnoid hemorrhage 
Reverses 
ischemia 
1. Hypervolemia, hemodilution and 
hypertension 
Reverses 
vasospasm 
1. Intra-arterial papaverine 
administration 
2. Percutaneous transluminal balloon 
angioplasty 
 
The presence of angiographic vasospasm 
within 48 hours of aneurysm rupture, as it 
was in our cases (at admission and detected 
on diagnostic angiography), although 
difficult to assess with certainty without a 
previous arteriography, has been correlated 
with a higher risk for later symptomatic 
vasospasm and a poor outcome (18). Our 
available options, in treatment of 
angiographic and clinical vasospasm, were 
the following: 
(a) early surgery 
(b)direct pharmacological arterial 
dilatation using calcium channel blockers 
(Nimodipine); using intra-arterial micro-
catheters, it was injected locally at the site of 
vasospasm, during control angiography 
(c) Indirect intra-arterial dilatation 
utilizing triple H therapy 
(d) Removal of potential 
vasospasmogenic agents (removal of blood 
clot and cerebrospinal fluid drainage) 
(e) Administration of plasma, dextran or 
albumin to enhance perfusion of the 
ischemic zones. 
As we previously underlined, two very 
important vasospasm treatment options, 
angioplasty and direct intra-arterial 
administration of papaverine, which were 
proved by several studies (6, 14) in 
reversing vasospasm, were not use in our 
clinic. 
Conclusion 
Many treatment strategies for combated 
angiographic and clinical vasospasm after 
aneurysmal subarachnoid hemorrhage have 
been described. Vasospasm remains an 
important clinical problem, a leading cause 
of preventable death and disability after 
SAH, and one of the most important 
independent predictors of poor outcome 
when it occurs. Intra-arterial administration 
of nimodipine is an important and useful 
treatment, but good results in reversal 
severe cerebral vasospasm are not always 
mandatory. In the future it is anticipated 
that better vasospasm prevention will be 
possible, likely through combined 
treatments, because vasospastic process is 
very complex. Nowadays, rescue treatment 
with hypervolemia, hypertension, and 
angioplasty is proved to be effective in 
reversing ischemia and preventing 
vasospasm-related morbidity and mortality. 
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